Abstract: A 6-O-sulfated N-acetylheparosan in which a primary hydroxyl group of N-acetylglucosamine constituting N-acetylheparosan is sulfated; a hematopoietic stem cell growth auxiliary agent, which has hematopoietic stem cell growth-accelerating activity and comprises the 6-O-sulfated-N-acetylheparosan as an active ingredient; a medium for a hematopoietic stem cell, which comprises the hematopoietic stem cell growth auxiliary agent and an other medium component necessary for culturing the hematopoietic stem cell; a method for culturing a hematopoietic stem cell, which comprises culturing the hematopoietic stem cell in the presence of the hematopoietic stem cell growth auxiliary agent or in the medium for a hematopoietic stem cell; and a method for treating a blood disease, which comprises transplanting a hematopoietic stem cell cultured by the above method to bone marrow of a mammal.

Abstract: The invention provides novel glycosaminoglycan derivatives having a repeating unit structure of two saccharides of hexosamine and hexuronic acid as a backbone structure, in which the bonds between 2- and 3-positions carbon atoms of hexuronic acid as its constituting monosaccharide are partially cleaved and a part or all of the 2-position hydroxyl groups of uncleaved hexuronic acid are not substituted with a sulfate group, which has low anticoagulation activity and excellent neurite outgrowth promotion accelerating activity and sialidase inhibition activity; a process for producing the glycosaminoglycan derivatives, comprising a cleavage treatment of the bond between the 2- and 3-position carbon atoms of hexuronic acid having no sulfate group at the 2-position of glycosaminoglycan, and a selective desulfation treatment of the 2-position sulfate group of hexuronic acid; and a pharmaceutical composition comprising the glycosaminoglycan derivative as an active ingredient.

Abstract: There is provided a glycosaminoglycan having a backbone structure comprising a repetitive disaccharide bearing a uronic acid residue and a glucosamine residue, and having sulfate groups, wherein substantially no sulfate group bound to the hydroxyl group at the 6-position of the glucosamine residue in the backbone structure is detected as determined by a chemical disaccharide analysis method in which the glycosaminoglycan is decomposed with nitrous acid, reacted with para-nitrophenylhydrazine and analyzed by high performance liquid chromatography, and the molar % of a uronic acid residue having a sulfate group at the 2-position is not less than 45% relative to total uronic acid residues, which is calculated from a disaccharide composition obtained by an enzymatic disaccharide analysis method in which the glycosaminoglycan is digested with glycosaminoglycan-degrading enzymes and analyzed by high performance liquid chromatography. The glycosaminoglycan can be used as an active ingredient of pharmaceuticals.

Abstract: In a data registering system, keyed-in data coupled from a key input section and voiced sound input data coupled from a microphone are compared in a sound controller and, when both the keyed in and voiced data coincide, subsequent calculation processing with the input data is allowed.